

Cambium Bio Limited

ABN 13 127 035 358

ASX Announcement

11 April 2024

Cambium Bio Appoints Dr. Yu-Hung Sebastian Tseng to the Board of Directors

Sydney, Australia; 11 April 2024: Cambium Bio Limited (ASX:CMB) (**Cambium Bio or Company**), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce the appointment of Dr. Yu-Hung Sebastian Tseng to the Company's Board of Directors, effective immediately.

Dr. Tseng is the Founder and Chairman of Zheng Yang Biomedical Technology Co., Ltd. (ZYBT), a prominent healthcare holding company based in Taiwan. He holds a Doctor of Dental Surgery degree from the College of Dentistry at New York University and has been a driving force behind the success of numerous healthcare ventures.

Through ZYBT, Dr. Tseng played a pivotal role in providing seed financing to Cambium Medical Technologies (CMT) in 2014 and subsequently securing follow-on financing for the business. His strategic vision and continued support have been instrumental in advancing the development of the Company's proprietary technology platform and lead product candidate, Elate Ocular, for the treatment of dry eye disease.

Management Commentary

Karolis Rosickas, CEO of Cambium Bio, commented, "We are delighted to welcome Dr. Tseng to our Board of Directors. Since the commencement of merger discussions with CMT, I have been thoroughly impressed by Sebastian's level of professionalism and his deep commitment to the success of our Elate Ocular dry eye technology. His extensive experience in the healthcare industry and his strategic insights will be invaluable as we navigate the next phase of our growth."

"I am confident that Sebastian's appointment will strengthen our Board's expertise and enhance our ability to execute on our strategic objectives. I look forward to working closely with him and the rest of the Board to progress Elate Ocular's Phase 3 studies and secure FDA approval, bringing us one step closer to providing a transformative treatment option for patients suffering from dry eye disease."

Dr. Tseng's appointment to the Cambium Bio Board of Directors underscores the Company's commitment to assembling a world-class leadership team with the skills and experience necessary to drive the successful development and commercialization of its innovative regenerative medicine pipeline.

About Cambium Bio Limited (formerly named Regeneus Ltd)

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio or www.regeneus.com.au.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.